LAB Q2 2021 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q2 2021 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$31M+19.0% YoY

Gross Profit

$16M52.9% margin

Operating Income

-$17M-55.7% margin

Net Income

-$17M-55.3% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

-5.4%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$19M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$289M

Total Liabilities

$180M

Stockholders' Equity

$109M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$26M	+19.0%
Gross Profit	$16M	$15M	+7.1%
Operating Income	-$17M	-$14M	-25.8%
Net Income	-$17M	-$13M	-31.7%

Revenue Segments

Product

$23M42%

Consumables

$12M23%

Instruments

$10M19%

Service

$7M12%

Product and Service, Other

$914,0002%

Grant

$821,0002%

License

$93,0000%

Geographic Segments

Americas

$16M52%

EMEA

$9M30%

Asia Pacific

$6M18%